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Abstract
Background. Arthrogryposis Multiplex Congenita, AMC, is a heterogeneous con-
dition defined as multiple congenital joint contractures in two or more body areas. 
The pathogenesis is impaired fetal movements. Amyoplasia, the most frequent form, 
is a sporadically occurring condition with hypoplastic muscles and joint contrac-
tures. Distal arthrogryposis (DA) syndromes are often hereditary, and joint involve-
ment is predominantly in hands and feet. Arhrogryposis with CNS involvement 
includes chromosomal and other syndromes. 
Aims. The purpose of this study was to investigate patients with arthrogryposis, to 
classify the different occurring forms, and to investigate causes, muscle and joint 
involvement, motor function, treatment and outcome.
Methods. Patients were identified via pediatric rehabilitation centers. Family and 
case history including perinatal findings were recorded. Physical investigation in-
cluded joint range of motion, muscle strength and motor function. In patients with 
DA molecular genetic and, in selected cases, muscle morphologic investigations were 
carried out. 
Results. 131 patients with arthrogryposis were investigated. The most frequent di-
agnoses were amyoplasia and DA. In amyoplasia, community ambulators had the 
best muscle strength, household ambulators had severe contractures in legs but good 
muscle strength in arms, and non-ambulators had the most severe contractures and 
muscle weakness. Muscle strength was found to be more important than joint range 
of motion for motor function.
In DA, muscle weakness was present in 44% of investigated patients. Mutations 
in sarcomeric muscle protein genes were found in seven families with autosomal 
dominant and in one child with sporadic DA. In one family with a mutation in 
TNNI2 there were mild myopathic findings, in one family with mutation in TPM2 
no obvious myopathy, and in patients from three families with MYH3 mutations 
mild myopathic findings. Clinical findings were found to be highly variable between 
families and also within families with DA. 
Conclusions. Different forms of arthrogryposis were identified. In amyoplasia, at-
tention should be directed at development of muscle strength with early stimulation 
of active movements. Immobilisation should be minimized. DA syndromes are clin-
ically and genetically heterogeneous conditions. Fetal myopathy due to sarcomeric 
protein dysfunction can cause DA. An early multidisciplinary team evaluation for 
specific diagnosis and planning of treatment is recommended.
Key words. Arthrogryposis, amyoplasia, distal arthrogryposis, muscle involvement, 
motor function, contractures, muscle morphology, sarcomeric protein dysfunction.
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Abbreviations
Abbreviations
ADHD  Attention deficit hyperactivity disorder
AMC  Arthrogryposis Multiplex Congenita
ATP   Adenosin triphosphate
BAC  Bacterial artificial chromosome
CA  Community Ambulator
CGH  Comparative genomic hybridisation
CHRNG Cholinergic receptor nicotinic gamma gene
CNS  Central Nervous System
CK  Creatine kinase
COFS  Cerebro-oculo-facio-skeletal
CT  Computed tomography
DA  Distal arthrogryposis
DNA  Deoxyribonucleic acid
EMG  Electromyography
FBN  Fibrillin gene
HA  Household ambulator
MCP  Metacarpophalangeal
MR  Mental retardation
MRI  Magnetic resonance imaging
MYH  Myosin heavy chain gene
MyHC  Myosin heavy chain
NA  Non ambulator
NADH  Nicotinamide adenine dinucleotide
NCS  Nerve conduction studies
NFA  Non functional ambulator 
PCR  Polymerase chain reaction 
RFLP  Restriction fragment length polymorphism
RNA  Ribonucleic acid
ROM  Range of motion
SD  Standard deviation
SMA  Spinal muscular atrophy
TM  Tropomyosin
Tn  Troponin
TNN  Troponin gene
TPM  Tropomyosin gene
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Introduction
introduction
In the field of neuromuscular disorders in children and adolescents, arthrogryposis 
is found to be a diverse and confusing diagnosis. Parents and professionals are often 
in doubt regarding specific diagnosis, treatment and prognosis in the child with 
arthrogryposis. This study was initiated by professionals treating arthrogryposis and 
by arthrogryposis patient organisations in Scandinavia. The study was conducted as 
a multicenter study with the investigators travelling to the local child rehabilitation 
centers in all health care regions of Sweden for personal interviews and investigation 
of included patients. The overall aims of the study were to clarify causes, clinical 
consequences and clinical course in arthrogryposis. 
Definition
Arthrogryposis Multiplex Congenita (AMC) is defined as congenital, non-progres-
sive contractures in more than two joints and in multiple body areas. The term 
arthrogryposis derives from the Greek words arthron – joint and grypos – curved. 
The term multiple congenital contractures can be used synonymously with arthro-
gryposis. The diagnosis is purely descriptive, and arthrogryposis can be part of a 
large number of different syndromes, at least 200 1. 
Compromised fetal mobility is the main background factor, common to all differ-
ent types of arthrogryposis. The cause can be pathology in the peripheral or central 
nervous system (CNS), in muscles or in connective tissue, defects in neuromuscular 
transmission, compromised space in utero, maternal disease, external factors like 
medication or drugs, or compromised vascular supply to the fetus 2.
Arthrogryposis refers to a large and heterogeneous group of conditions, both sporad-
ically occurring and hereditary. The literature is confusing regarding types of arthro-
gryposis described, as different diagnoses are often lumped together and regarded as 
one entity. The most frequently occurring form of arthrogryposis is amyoplasia 3, a 
sporadically occurring condition sometimes referred to as “classical arthrogryposis”. 
The second most common form is probably distal arthrogryposis, (DA) 4, 5. DA is not 
one single entity, but a group of syndromes with mainly distal joint contractures 6, 7. 
Background
Historically, a patient with AMC is described by Thomas of Monmouth in “The 
life and Miracles of St William of Norwich” in 1156, as reported by Gordon 8. A 
boy with arthrogryposis is depicted in a painting by Jusepe de Ribera (“The club 
foot”) from 1642 9. The first description of arthrogryposis in the medical literature 
is thought to be by AW Otto, professor of anatomy in Breslau, in a textbook from 
1841 10. The term Arthrogryposis was probably first used by Rosencranz in 1905 11, 
and the term Arthrogryposis Multiplex Congenita by Stern in 1923 12. The term 
Amyoplasia Congenita is used by Sheldon in 1932 13.
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AMC is discussed and described in orthopedic reviews from 1930 to 1950, and nu-
merous specific syndromes with AMC are described in the medical literature from 
1950 to 1960. Further research regarding the pathogenesis was published in the fol-
lowing decades 12, 14-16. Hall described clinical and genetic evaluation and diagnosis 
in patients with AMC 17, 18. There are a great number of publications on genetic diag-
nostics and further descriptions of mechanisms leading to reduced fetal mobility. 
Recently, advances in molecular genetics have made it possible to understand patho-
genic mechanisms, especially in distal arthrogryposis (DA) syndromes, where  mu-
tations in genes that encode for contractile muscle proteins have been found 19-22. 
Pathogenesis
Animal studies demonstrate that congenital joint contractures can be caused by fetal 
immobilization. A study from 1962 by Drachman and Coloumbre showed that con-
genital joint ankylosis can be produced by relatively short periods of immobilization 
in chick embryos 16. In 1983, Moessinger (1983) 14 published an animal study where 
rat fetuses paralysed during part of gestation showed the same anomalies as those 
described in Pena Shokeir I syndrome: multiple joint contractures, pulmonary hy-
poplasia, micrognathia, fetal growth retardation, short umbilical cord, and polyhy-
dramnios. These features were previously described by Pena and Shokeir in an early 
lethal disorder with autosomal recessive inheritance, Pena Shokeir I syndrome 23.
Polyhydramnios is thought to be due to lack of swallowing during fetal life. Oli-
gohydramnios deformation sequence includes similar features, also demonstrated 
in animal studies, possibly caused by fetal immobilization from external factors. 
However, renal defects are also often present in oligohydramnios 15.
Swinyard 12 discusses the etiology of multiple congenital contractures in animals 
and in humans and suggests that the joint fixations are caused by a proliferation 
of capsular connective tissue, a compensatory connective tissue response to lack 
of movement in utero.
Hall (1986) suggested that the Pena Shokeir syndrome represents a phenotype, 
fetal akinesia deformation sequence, caused by severely decreased or absent fetal 
movements 24, including joint contractures, short gut, pulmonary hypoplasia, 
short umbilical cord, intrauterine growth retardation, and craniofacial abnor-
malities. At least 20 familial types of Pena-Shokeir phenotype are now recog-
nized, in addition to sporadic cases 25.
Pathologic changes in 96 children with AMC were described in a study by Bank-
er in 1986 15. Abnormalities in the neuromuscular system were found in all cases, 
with the primary alterations in anterior horn cells, roots, peripheral nerves, mo-
tor end-plates or muscles. All had onset during fetal development. The vast ma-
jority of patients in this study were considered to have a neurogenic cause. Dys-
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genesis or degeneration of the spinal cord, with abnormalities in anterior horn 
cells, were found in a majority of cases with CNS involvement, while the spinal 
cord and anterior roots were normal in myopathic cases (e.g. central core disease, 
congenital muscular dystrophy, nemaline myopathy, myotonic dystrophy). Fiber 
type predominance or disproportion was also found in some patients, in whom 
involvement of the spinal cord was not seen. Presumably secondary changes of 
muscle included fiber type predominance and disproportion, aplasia of muscle 
(amyoplasia) signifying a primary defect in the anterior horn cells early in the 
fetal development leading to hypoplasia of muscle and progressive denervation 
of muscle. CNS involvement included dysgenesis or degeneration of the brain 
and/or spinal cord in association with cases of trisomy 18, trisomy 21, Möbius 
syndrome, Zellweger syndrome, spinal muscular atrophy, and others.
In a further pathology study of 83 cases of lethal arthrogryposis in Finland, the 
majority of cases were also found to have a neurogenic cause, a few myopathic, 
while a non-neuromuscular cause was present in 10 cases 26.
Investigation of the spinal cord in infants with neurogenic arthrogryposis has 
demonstrated abnormal histology and unequal distribution of alpha motor neu-
rons in anterior horn cells, the latter also predictive of involved muscle groups 27. 
Several studies report that neurogenic arthrogryposis (of the amyoplasia type) 
can be caused by vascular compromise in early fetal development, with ischemia 
of anterior horn cells leading to fetal akinesia and poor or absent muscle develop-
ment, but also in some cases to co-existing anomalies with presumed vascular 
genesis, i.e. gastroschisis, bowel atresia, Möbius syndrome, and focal muscle de-
fects 28-31.
Arthrogryposis can be present in several congenital myopathic disorders, e.g. ne-
maline myopathy 32, centronuclear myopathy 33, central core disease and others, 
in congenital muscular dystrophies (Fukuyama, Ullrich) 1, in severe SMA1 with 
fetal onset 34, and in severe congenital polyneuropathies 35-37.
Several DA syndromes have recently been discovered to be caused by mutations 
in sarcomeric muscle proteins 19-22. A number of collagen disorders can also ap-
pear with arthrogryposis, for example Ehlers-Danlos syndrome 38, Marfan syn-
drome 39 and Larsen syndrome. DA9, Beal syndrome, has also been found to be 
a collagen disorder with a mutation in the FBN2 gene 40.
Disease affecting the neuromuscular junction with resulting weakness can cause 
arthrogryposis. Congenital myasthenic syndrome with arthrogryposis has been 
reported 41, congenital myotonic dystrophy 42, and maternal antibodies to fetal 
neurotransmittors 43 can all cause arthrogryposis.
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Movement restriction in utero caused by e.g. oligohydramniosis, myoma/fibroma 
of the uterus and bicornate uterus can be associated with arthrogryposis. Ar-
throgryposis of the amyoplasia type occurs with increased frequency in one of 
monozygotic twins, but the cause in these cases is thought to be more related to 
vascular compromise than to actual crowding 28, 44. 
A separate group of arthrogryposis syndromes are those caused by maternal dis-
ease during pregnancy, such as maternal multiple sclerosis, maternal myasthenia 
gravis 1, maternal diabetes mellitus, and maternal hyperthermia 1. Metabolic dis-
ease such as phosphofructokinase deficiency can cause arthrogryposis and drugs 
taken during pregnancy can also be associated with arthrogryposis (e.g. muscle 
relaxants, misoprostol, cocaine, alcohol)1. 
Contractures caused by compromised space in utero have a relatively late ges-
tational onset and are relatively mild. These types of congenital contractures 
regress more easily compared to contractures caused by early immobility of the 
fetus 45.
Epidemiology
Several epidemiological surveys of arthrogryposis have been published. The occur-
rence has previously been estimated to 1 in 3,300 live births in a Finnish study from 
1966 46, 1 in 56,000 live births in a Scottish study of 66 sporadic cases from 1976 47, 
and 1 in 12,000 live births in a study from Western Australia from 1976 48. 
In a retrospective epidemiologic study in western Sweden by Darin et.al., all chil-
dren born with multiple congenital contractures between 1979 and 1994 were iden-
tified through screening of registers, reviews of medical records and re-examination 
of children. 68 cases were identified, and the birth prevalence was found to be 1 in 
5,100 live births 49. In this study, 39 patients had cerebral or spinal involvement, 
three patients had mechanical restriction in utero, 12 neuromuscular and nine con-
nective tissue involvement. 
Clinical classification
Since there is a very large number of disorders with arthrogryposis, differential di-
agnosis can be difficult. It is, however, important to make as specific a diagnosis as 
possible for several reasons:
Treatment can vary depending on the underlying cause in the individual child. For 
example, stretching should be minimized in diastrophic dysplasia, where too in-
tensive mobilisation may damage joint cartilage. The joint contractures can also be 
more resistant to treatment in certain types of AMC, especially amyoplasia 50 and 
surgery and splinting may need to be planned accordingly.
Risk of re-occurrence varies greatly: amyoplasia occurs sporadically, while several 
forms of DA have autosomal dominant inheritance with a recurrence rate of 50%. 
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The prognosis is also very much dependent on diagnosis, where conditions with 
CNS involvement may have a poor prognosis, sometimes with early death, while 
other conditions have a normal lifespan but may need extensive orthopaedic treat-
ment and rehabilitation.
An approach to clinical evaluation that has been found to be very useful has been 
suggested and further developed by Hall 1, 17, 18. According to this, patients can be di-
vided into three main groups of disorders: 1 Primarily musculoskeletal involvement; 
2 Musculoskeletal involvement plus other system anomalies and, 3 Musculoskeletal in-
volvement plus central nervous system dysfunction and/or mental retardation (MR).
Amyoplasia or “classic arthrogryposis” belongs to the first group, as do several camp-
todactyly syndromes, distal arthrogryposis type 1, popliteal pterygium syndrome, 
several symphalangism syndromes, and others. 
In the second group, i.e. involvement of limbs and other body areas, several other 
camptodactyly syndromes, several DA syndromes, myotonic dystrophy, congenital 
myopathies, myasthenia gravis, connective tissue disorders such as Larsen syndrome and 
Marfan syndrome with congenital contractures can be included. 
The third group includes a great number of genetic syndromes and chromosomal 
anomalies. Examples from this group are COFS (cerebro-oculo-facio-skeletal) syn-
drome, congenital muscular dystrophy, Miller-Dieker (lissencephaly), lethal mul-
tiple pterygium syndrome, Pena-Shokeir phenotype, Potter syndrome, Zellweger 
syndrome, trisomy 8/mosaicism, trisomy 18, and many others. This group includes 
lethal syndromes and syndromes with severe disabilities due to central nervous sys-
tem malfunction. Mental retardation/CNS involvement is found in approximately 
25% of individuals with AMC 2, 51, 52.
Figure 1. Two children with arthrogryposis and CNS involvement at age six years (left) 
and one year (right). Note tracheostomy and gastrostomy in the girl to the left in the pic-
ture. Photographs are published by permission of the parents.
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Investigation
To clarify the specific diagnosis in a child with arthrogryposis, a careful clinical 
evaluation including joint mobility, muscle strength, and associated anomalies is 
important. Family history, pregnancy history including infections, trauma, bleed-
ing, drugs and medication, delivery history, developmental milestones in an older 
child, and associated problems should all be recorded. Evaluation of the mother of a 
newborn child with arthrogryposis should not be overlooked, regarding e.g. mater-
nal myasthenia or myotonic dystrophy.
Possible CNS involvement must be evaluated. Ultrasound/CT scan or MRI of the 
brain should be performed if there are signs of CNS involvement, and also MRI of 
the spinal cord if there are signs of spinal involvement. Muscle ultrasound 53, CT-
scanning of skeletal muscle 54, and MRI of muscle 55 can all be helpful in evaluating 
affected muscle involvement in planning muscle biopsy or surgery, and also to follow 
muscle development over time.
Dysmorphic features, which could indicate chromosomal anomalies, should be 
looked for and, if present, chromosomal analysis should be performed. Microar-
ray based Comparative Genomic hybridisation (arrayCGH), is a method which in 
recent years has proved to be a reliable diagnostic tool for genome-wide detection 
of small chromosomal abnormalities, copy number changes, in patients with MR. 
Studies have demonstrated arrayCGH to detect copy number variations in 10-20% 
of patients with mental retardation with and without dysmorphic features and/or 
multiple congenital anomalies 56-59.
If there is any suspicion of myopathic involvement serum muscle enzymes should be 
analyzed. Other blood or urine chemistry investigations, such as serum lactate and 
metabolic screening, should be carried out if indicated from clinical findings (such 
as suspicion of mitochondrial or metabolic disease)
Nerve conduction studies, NCS, can be helpful if there are signs of peripheral nerve 
involvement/polyneuropathy, and electromyography, EMG, if there are signs of 
myopathy.
Muscle biopsy for pathological evaluation is essential for a correct diagnosis in myo-
pathic conditions 15, and can be of help if the diagnosis is unclear 60. Therefore, if 
orthopedic surgery is planned a muscle biopsy should also be considered. 
In a study of the diagnostic value of NCS/EMG and muscle biopsy in the evaluation 
of 38 patients with AMC, it was found that when clinical evaluation suggests a spe-
cific syndrome, developmental, or exogenous cause, NCS/EMG and muscle biopsy 
are not helpful, but when the diagnosis is unclear NCS/EMG and muscle biopsy 
together can help in the diagnostic workup 61. 
In two muscle morphologic studies from patients with neurogenic AMC 62 and AMC 
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where known myopathic conditions were excluded 63, findings indicating neurogenic 
cause were found, i.e. variation in fiber size and abnormal fiber type distribution.
With careful evaluation and investigation, a specific diagnosis can be reached in at 
least 30-50% of individuals with arthrogryposis 1. Prenatal diagnosis of AMC by 
ultrasound is possible, assessing fetal movement 64.
Family history
Clinical investigation
– Joint involvement
• Proximal/distal
• Jaws
• Spine
• ROM, range of motion
– Muscle involvement
• Absence/hypoplasia of muscles
• Muscle weakness
– Other organ involvement
• Eyes, palate, heart, lungs, 
gastrointestinal, genitourinary system
– Cognitive function
– Developmental history
– Associated problems/disease
Functional assessment
– Gross motor function
– Hand function
– ADL, activities of daily living
Laboratory investigations
– Genetic tests
• Chromosomes, 
• DNA-analysis (if signs of specific
genetic syndrome) 
– Blood chemistry:
• lactate, muscle enzymes,
– MRI of brain/spinal cord if signs of CNS 
involvement
– CT/MRI of muscles in amyoplasia
– EMG if signs of myopathy
– NCS if signs of polyneuropathy
Figure 2. Suggested baseline investigations in arthrogryposis.
Treatment  
Physical therapy, splinting, and orthopedic surgery are the main treatment methods 
in arthrogryposis 45. A correct genetic diagnosis is important, as treatment needs 
may vary 65-67. 
Early physical therapy is important to avoid further muscle atrophy and, for the 
same reason, splinting combined with physical therapy is mostly preferable to cast-
ing, especially in amyoplasia 1, 5. The first three to four months of life are especially 
valuable in activating and stimulating muscle function and in stretching contracted 
joints 66. Daily passive stretching and serial splinting in infants has been found to 
increase function 68.
Children with arthrogryposis may have major feeding difficulties in infancy, i.e. 
problems with chewing, sucking, and swallowing, sometimes requiring tube feed-
ing. These problems are in many cases related to structural abnormalities in the jaw 
and tongue. Secondary to this chest infections, constipation, poor growth, and also 
language problems can be seen 69. 
Malignant hyperthermia can occur in some forms of arthrogryposis, which must 
20
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be kept in mind prior to anesthesia for orthopedic and other surgery. Maxillar and 
mandibular dysplasia and limited mouth opening are common problems, which can 
make intubation difficult 70, 71. 
A multidisciplinary team management is needed, as many aspects need to be taken 
into account in the planning of treatment to optimize the child s´ functional out-
come. In planning treatment, the child s´ general development and social activities 
must be kept in mind. A considerable part of the child s´ day may be occupied by 
physical therapy and training 65. The goal of treatment must be to achieve indepen-
dence in adult life, and there must also be time for play and other important activities 
in daily life. Factors of importance to achieve independence are, in order of impor-
tance, communication skills, activities of daily living, mobility, and walking 5, 50.
Figure 3. Two boys with amyoplasia at ages three years (left) and 2.5 months (right). 
Photographs are published by permission of the parents.
Amyoplasia 
The most common form of arthrogryposis is amyoplasia, which accounts for ap-
proximately one third of all cases 3. The word amyoplasia means no muscle forma-
tion. Amyoplasia occurs sporadically. Pathogenesis is unknown but thought to be 
impaired blood circulation to the fetus early in pregnancy with hypotension and 
hypoxia damaging the anterior horn cells and resulting in lack of or underdevelop-
ment of muscle tissue with fatty or connective tissue replacement 3, 72. Clinically, 
the common morphologic features suggest a genetic syndrome, but occurrence is 
sporadic and individuals with amyoplasia have unaffected children 1. Amyoplasia 
occurs in increased frequency in one of monozygotic twins 73. 
The diagnostic criteria for amyoplasia are highly specific with decreased muscle 
mass, typical joint contractures and limb positioning at birth, mostly symmetrical 
in all four limbs. There may be involvement only of the lower limbs or, less com-
monly, only of the upper limbs and asymmetric limb involvement 3, 74. Typically, the 
shoulders are adducted and internally rotated, and the elbows are extended with the 
forearms pronated and wrists and fingers flexed. The hips are either in abduction and 
external rotation with flexed knees, or flexed with extended or flexed knees. Hips 
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and knees can be dislocated. The feet are most often in an equinovarus adductus 
position, although other types of foot deformities occur. Involvement of the spine is 
also described 3, 74. The contractures can be fixed or flexible. 
There is usually dimpling of the skin over affected joints. Common associated find-
ings are midline facial hemangiomas and a round facial appearance. Muscle defects 
in the abdominal wall and inguinal hernias occur in about 10% of children born 
with amyoplasia, and gastroschisis and bowel atresia have also been recorded 28. 
Mental development is normal 74, unless there has been a concomitant birth as-
phyxia.
Contractures in children with amyoplasia are at their maximum at birth. To increase 
the joint range of motion (ROM) and to obtain a functional position of the joint, a com-
bination of stretching, splinting, and orthopedic surgery is often necessary 65, 66, 68. Early 
physical therapy is very important, both to mobilize joints and to stimulate muscle 
growth and to prevent further muscular atrophy 50. In amyoplasia, the joint contrac-
tures can be severe and have a tendency to recur after correction 65.
Figure 4. Eight months old girl with familial DA and a pathogenic mutation in TNNI2 
(left) and hands of a one year old boy with familial DA and no identified gene mutation 
(right). Photographs are published by permission of the parents.
Distal arthrogryposis
Clinical classification
Distal arthrogryposis (DA) syndromes are characterized by mainly distal congenital 
joint contractures, i.e. in the hands and feet. The exact incidence of DA is not known. 
In a large study of over 350 patients with arthrogryposis, 44 (12,6%) patients with 
DA were identified 6. In another review, 35% of 155 patients with artrogryposis were 
diagnosed with DA 5. In an epidemiological survey from western Sweden, 5 (7%) 
patients with DA syndromes were identified in a total of 68 patients with multiple 
congenital contractures 49.
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Table 1. Classification of DA syndromes
Distinguishing features Classification 
Hall
Classification
Bamshad
Other  name
Overlapping fingers neona-
tally, ulnar deviation
DA type I DA1 Digitotalar dysmorphism
Facial contractures,
small pursed mouth
DA2A Freeman Sheldon 
syndrome, FSS
Intermediate DA1/2A DA2B Sheldon Hall syndrome
Cleft palate, short stature DA type IIA DA3 Gordon syndrome
Scoliosis DA type IID DA4 Arthrogryposis with 
severe scoliosis
Cleft lip DA type IIC
Ptosis, limited ocular mobility DA type IIB DA5 Arthrogryposis with 
oculomotor limitation and 
electroretinal 
abnormalities
Sensorineural hearing loss DA6 Arthrogryposis-like hand 
anomaly and s
ensorineural hearing loss
Trismus, facultative finger 
contractures
DA type IIE DA7 Trismus-pseudocampto-
dactyly syndrome, Hecht 
syndrome
Multiple pterygium DA8 AD multiple pterygium 
syndrome
Ear deformity, long fingers DA9 Beal syndrome, 
congenital contractural 
arachnodactyly 
Plantar flexion contractures DA10 Short tendo calcaneus
DA has been defined as arthrogryposis with congenital hand and foot involvement 
by Hall et. al. in 1982 6: type I with only distal joint involvement and characteristic 
hands at birth with flexed and overlapping fingers, and type IIA-IIE with distal limb 
contractures and additional characteristic manifestations.
A revised and extended classification was made by Bamshad et.al. in 1996 7. In this 
classification, DA is defined as an inherited primary limb malformation disorder 
characterized by congenital contractures of two or more different body areas and 
without primary neurological and/or muscle disease that affects limb function. In-
cluded disorders are characterized by distal joint involvement, limited proximal joint 
involvement, autosomal dominant inheritance, reduced penetrance, and variable ex-
pressivity. In this classification, nine different clinical forms are originally described, 
with a 10th syndrome defined in 2006 7, 75.
The prevalence of DA syndromes is not known. The most commonly described 
forms of DA are DA1 and DA2B. DA1 is characterized by clenched fists at birth, ul-
nar deviation, medially overlapping fingers and club feet or other foot malpositions. 
23
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The hips may be affected, calves small and opening of the mouth mildly limited 76. 
DA2B, Sheldon Hall syndrome, is similar to but milder than DA2A 4, 77. DA2A, 
Freeman Sheldon syndrome, is characterized by a small mouth, facial contractures, 
scoliosis, mainly distal joint contractures and short stature 77. Typical findings in 
DA2B are vertical talus, ulnar deviation, severe camptodactyly, triangularly shaped 
face, prominent nasolabial folds, downslanting palpebral fissures, small mouth and 
prominent chin 4. Foot deformities may be asymmetric 78. 
The sarcomer is the functional unit of striated muscle contraction. Mutations in sar-
comeric proteins are found in at least 20 different skeletal muscle diseases 79 and can 
result in DA or in congenital myopathy 33. Mutations in genes encoding sarcomeric 
muscle proteins are found in several DA syndromes: Sung et.al. described mutations 
in β tropomyosin (TPM2) in DA1, and mutations in fast troponin I (TNNI2) and 
fast troponin T (TNNT3) in DA2B 19. Toydemir et. al. describes mutations in em-
bryonic myosin heavy chain (MYH3) in DA2A, Freeman Sheldon syndrome, and in 
DA2B, Sheldon-Hall syndrome 21. Further, a mutation in fetal myosin heavy chain 
(MYH8) has been described in DA7, trismus-pseudocamptodactyly syndrome 22. A 
defective function of contractile muscle proteins during fetal life influencing fetal 
mobility seems to be the common cause of congenital joint contractures in these 
syndromes 21, 22.
Gene mutations and sarcomeric muscle proteins in DA
Two different mutations in the gene encoding an isoform of troponin I (TnI) specific 
for fast-twitch muscle fibers (TNNI2) have been associated with DA2B. DA2B has 
also been associated with a mutation in the gene encoding an isoform of troponin 
T specific for fast twitch contractile proteins (TNNT3) 20. DA1 has, in one affect-
ed family, been associated with a mutation in the gene encoding β-tropomyosin 
(TPM2), 80 which is expressed mainly in slow twitch muscle fibers 81.
Figure 5a. Sarcomeric proteins in the thin (actin) filament(top) and thick (myosin) fila-
ment (bottom) in striated skeletal muscle. The thick and thin filaments slide past each 
other in muscle contraction. Figure by Homa Tajsharghi, reproduced by permission.
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Figure 5b. The sarcomere is divided into four major components: the Z-disc, I band, A 
band and M-line, with one sarcomere stretching from one Z-disc to the next. Figure by 
Homa Tajsharghi, reproduced by permission.
The thin filament in striated muscle contains actin, tropomyosin, nebulin, and the 
troponin complex (TnI, TnT, and TnC). TM is composed of two α-helical chains, 
forming a rod-shaped coiled-coil dimer. It is localized head to tail along the length 
of the actin filament, providing stability, and is essential for myosin-actin interac-
tion 81, 82. 
There are four TM genes: TPM1, TPM2, TPM3, and TPM4. By alternative splicing, 
the use of alternative promoters and differential RNA processing, various transcripts 
are produced, which are specific for striated muscle, smooth muscle, and nonmuscle 
tissues 81. 
There are three primary striated muscle TM isoforms, α-TM, β-TM, and γ-TM, 
which are highly homologous but are thought to exhibit unique physiologic proper-
ties 81. In human striated muscle, α-TM is a product of TPM1, β-TM is encoded from 
TPM2, and γ-TM is encoded from TPM3. These striated muscle-specific isoforms 
are expressed in developmental and fiber-type-specific patterns in skeletal muscle 
and heart 81, 83. In humans, the muscle isoform encoded by TPM1 is predominantly 
expressed in cardiac muscle and in fast type 2 muscle fibers. TPM2 is mainly ex-
pressed in slow  type 1, and, to some extent, in fast muscle fibers and cardiac muscle. 
TPM3 is predominantly expressed in slow muscle fibers and is also expressed in the 
heart 81. In one family, DA1 was caused by the substitution of a highly conserved 
amino acid residue (R91G) in TPM2 19.
Myosin is the main component of skeletal muscle sarcomeric thick filaments. It 
consists of two globular heads attached to a long-helical-coiled coil rod domain. It is 
a hexamer composed of one pair of myosin heavy chains (MyHCs) and two pairs of 
myosin light chains. The myosin globular head domain of the myosin motor (myo-
sin subfragment 1 [S1]) contains actin and adenosine triphosphate (ATP)-binding 
regions and is responsible for the force transduction properties of myosin 84. 
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Several striated muscle MyHC genes have been described 85. The expression of my-
osin isoforms is developmentally regulated 86-88. Myosin myopathies have evolved 
as a new group of muscle diseases caused by mutations in skeletal muscle myosin 
heavy-chain (MyHC) genes. The phenotypes of these diseases vary, ranging from 
prenatal nonprogressive arthrogryposis syndromes to adult-onset progressive muscle 
weakness. Mutations have been reported in two of three MyHC isoforms expressed 
in adult limb skeletal muscle. In addition to familial hypertrophic or dilated cardio-
myopathy 11 mutations in the slow or cardiac MyHC gene (MYH7) cause skeletal 
myopathies such as myosin storage myopathy 89-93 and Laing early-onset distal myo-
pathy 94, 95. A mutation in the MyHC IIa gene (MYH2) is associated with dominant 
myopathy characterized by ophthalmoplegia, congenital joint contractures, and 
rimmed vacuoles in muscle fibers 96-98.
DA2A, Freeman-Sheldon syndrome, and DA2B, Sheldon-Hall syndrome, have 
been reported as the first disorders associated with mutations in embryonic MyHC 
(MYH3)21.  DA syndromes are associated with missense mutations in various genes 
coding for sarcomeric proteins. The genes thus far demonstrated to be involved in 
DA syndromes are TNNI2 (troponin I), TPM2 (β-tropomyosin) 19, TNNT3 (tro-
poninT) 20, MYH8 (perinatal MyHC), and MYH3 (embryonic MyHC)21.
These findings indicate that DA syndromes are caused by myopathies with onset 
during fetal development, but few studies have involved analysis of muscle tissue in 
these diseases. 
In a recent study aiming to investigate the mechanisms of impaired muscle function 
in two patients with DA2B and a β-tropomyosin mutation (R133W), significant 
differences in regulation of muscle contraction was demonstrated in type 1 fibers. 
The found mutation appears to induce alteration in myosin-actin kinetics causing a 
reduced number of myosin molecules in the strong actin-binding state, resulting in 
muscle weakness in the absence of muscle wasting 9.
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Aim
aims of the study
The aims of the study were:
 
• To investigate children and adolescents with arthrogryposis in Sweden and to  
   classify the different occurring forms.
• To describe a group of individuals with amyoplasia, to investigate how muscle   
   strength and joint contractures affect their motor function, and to relate their    
   current functional status to joint position at birth.
• To investigate the clinical, muscle morphologic and genetic findings in families  
   with DA and pathogenic mutations in the sarcomeric muscle protein genes     
   TNNI2, TPM2 and MYH3.
• To describe the clinical findings, clinical course, additional problems and    
   disabilities in 40 individuals with DA and to evaluate genotype-phenotype    
   correlation. 
• To study and evaluate given treatment in patients with amyoplasia and DA.
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Methods
material and methods
Patients
In a national survey in Sweden, 127 children, adolescents and young adults with 
arthrogryposis were investigated. The index patients were identified through pediat-
ric rehabilitation centers or, in a few cases, through the orthopaedic surgeon or the 
Swedish AMC-association. A further four children with familial DA were added to 
the study after the initial survey was completed, making the total number 131. 
The inclusion criteria were contractures present at birth in more than two joints and 
in multiple body areas. Children born with myelomeningocele, isolated congenital 
hip dislocation or pes equinovarus adductus were excluded.
Written informed consent was obtained from adult participating individuals and for 
participating children, from the parents. 
The study was approved by the Ethical Board at the Universities of Gothenburg, 
Uppsala, Stockholm, Umeå, Örebro, Malmö, Lund and Linköping, and by the 
heads of Paediatric clinics in the Swedish health-care regions.
INTERVIEW and RECORDS
• Patient data, background factors
(family history, pregnancy etc)
• Neonatal findings
• Results from investigations
• Given treatment
• Course, development
• Activities of daily living (ADL)
• Social/school, rehabilitation 
contacts
• Functional aids
CLINICAL INVESTIGATION
• General physical examination
• Joint mobility (ROM)
• Muscle strength
– Manual muscle testing 
– Myometry
• Timed functional tests
• Evaluation of 
– Gross motor function
– Hand function
– Reaching ability
• Language, communication
• Photo and video documentation
Figure 6. Summary of performed investigations in the survey of children and adolescents 
with arthrogryposis in Sweden.
Clinical investigation
All patients were investigated by the same pediatric neurologist (EK) and physio-
therapist (AKK). Interview with the families, examination of the patients, and re-
view of medical records were carried out at the local child rehabilitation centers. 
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A structured interview including family history, prenatal and perinatal history, neo-
natal findings including joint involvement, developmental milestones, associated 
medical problems, treatment, and outcome was carried out for all index cases.
 
A detailed clinical examination was carried out. Physical examination included eval-
uation of facial involvement, other associated signs and symptoms and a neurologi-
cal examination.
For each patient, medical records were studied and results from previous investi-
gations, including orthopedic procedures and muscle biopsies, were recorded. In 
patients with amyoplasia (paper I), an orthopedic surgeon (RJ) also reviewed the 
orthopaedic treatment records.
Affected adult family members were also examined by the same physician and phys-
iotherapist, and information on family history was obtained by personal interviews. 
Extended family members who were found to be asymptomatic carriers of the patho-
genic gene mutation in the family were seen and interviewed personally to exclude 
the presence of previously undiagnosed distal joint involvement.
Diagnosis was determined based on clinical findings and medical records, using 
known diagnostic criteria. For all patients with dysmorphic signs and/or suspected 
genetic syndrome, clinical findings and features of the patients were discussed with 
a clinical geneticist and in some cases a search in a genetic data base, Possum, was 
performed to aid in the diagnosis. Short stature was defined as below 3 SD. Cardiac 
investigation was performed in two patients with DA and TPM2 mutation.
Figure 7. Measuring muscle strength by a hand-held dynamometer.
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Muscle strength
Isometric muscle strength was measured with an electronic hand-held dynamometer 
(adapted Chatillon, Axel Ericson Medical AB, Göteborg, Sweden) with a method 
standardized by Eek et.al. 100 or, in children too young to participate, by clinical 
evaluation. Nine muscle groups were measured. An isometric contraction of at least 
five sec was required and the peak force value in Newton was recorded. The best of 
three values obtained was compared with the mean value from weight-related refer-
ence values for healthy children and adolescents 100. To be able to compare isomet-
ric muscle strength independent of age and gender, a percentage of normal muscle 
strength was calculated.
Range of motion, ROM
Passive ROM was measured with an ordinary goniometer. Information on hip dis-
location was collected from medical records.
Motor function
Motor function was assessed using a scale designed by Scott et.al. 101. Twenty move-
ments were assessed, including head-lifting in the supine position, rolling, sitting 
up from lying down, sitting, getting off a chair, standing up from lying, standing, 
standing on heels, standing on toes, standing on one leg, jumping, and climbing up 
and down stairs. The performance is scored according to a three-point scale: 0 (un-
able), 1 (needs self-reinforcement), and 2 (succeeds). Maximum score is 40. 
Figure 8. A three-year-old girl with amyoplasia using orthoses and walker. Level of 
ambulation was household ambulator. The photograph is published by permission of the 
parents. 
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According to their level of ambulation the patients were divided into functional 
groups according to the classification of Hoffer et al 102:
1. Community ambulators (CA) walk with aids in the community and do not need 
    a wheelchair;
2. Household ambulators (HA) walk with aids in the household and use a wheel 
    chair in the community;
3. Non-functional ambulators (NFA) use parallel bars or walkers with support;
4. Non-ambulators (NA) do not walk.
Figure 9. Illustration of hand involvement in a child with amyoplasia (left) and a child 
with distal arthrogryposis (right).
Hand function
Hand function was evaluated as follows: The ability to grasp a piece of paper, grasp 
a pencil, draw/write, build with duplo and lego bricks, thread beads on a string and 
screw a nut and bolt was evaluated and videotaped in all investigated children from 
the age of four years. In younger children hand function was observed and video-
taped during play. 
Four categories of hand function were used:
1. Normal function;
2. Able to perform all tasks completely but with compensatory strategies;
3. Able to perform all tasks but incompletely and with compensatory strategies;
4. Able to perform tasks incompletely, very limited hand function.
Blood chemistry and neurophysiology
Serum creatine kinase (S-CK) concentrations were measured in affected individuals 
with DA. In one individual, urine myoglobin levels before and after exercise were 
measured and electromyography (EMG) was performed.
Muscle morphology
In 11 individuals muscle biopsies were obtained and analysed by the same pathologist 
(AO). In five patients, results from previously performed muscle biopsies were recorded 
from medical charts. Morphologic stainings included hematoxylin–eosin and Gomori 
trichrome. Histochemical analyses included myofibrillar ATPase, oxidative enzymes 
(NADH-tetrazolium reductase, succinate dehydrogenase, and cytochrome oxidase), 
glycogen, lipids, and major histocompatibility complex class 1 antigen.
33
Methods
To identify embryonic (MYH3) MyHC expression, a monoclonal antibody, F1.652 
(Developmental Studies Hydridoma Bank, Department of Biologic Sciences, Uni-
versity of Iowa, Iowa City), at a concentration of 1:100 was used.
In muscle tissue from four patients with DA and MYH3 mutations, investigation of 
expression of MYHC isoforms at the protein and transcript levels were carried out 
in addition to morphologic analysis. 
Molecular genetic investigation
Blood samples for genetic analysis were obtained and analysed from 25 index pa-
tients with DA and from their relevant family members. Blood samples were also 
obtained from 11 patients with CNS involvement/MR and dysmorphic signs, with 
normal karyotype on previous investigation.
Distal arthrogryposis
Extraction of genomic DNA, polymerase chain reaction (PCR) and sequence analy-
sis were performed. The entire coding sequence of MYH3, TPM2 and TNNI2 was 
sequenced in relevant patients using a previously described primer. The presence of 
each mutation was confirmed in each affected individual by restriction fragment 
length polymorphism (RFLP) analysis. The RFLP was also used to screen for the 
presence of each mutation in 200 control chromosomes. The entire coding region of 
MYH3, TPM2, and TNNI2 genes was sequenced in 14 patients. In a few patients, 
in whom mutations in MYH3, TPM2 and TNNI2 had been excluded, TNNT3, 
TNNT1, TNNC1, TNNC2 and TNNT1 were also analysed. In one patient, the ace-
tylcholine receptor gene gamma, CHRNG, was investigated in addition to TPM2.
CNS involvement and dysmorphic signs
In 11 cases of arthrogryposis with CNS-involvement/MR and dysmorphic signs, 
where routine chromosome analysis had been normal but clinical signs suggested a 
chromosomal background, further investigation with arrayCGH, was performed. 
Eight patients were analyzed by arrayCGH consisting of 32 000 BAC clones as pre-
viously described by de Ståhl et al and three patients by Affymetrix 250K Nsp array 
according to the standard Affymetrix GeneChip protocol (Affymetrix Inc, Santa 
Clara, California, USA). 
Statistical analysis (paper I) 
Stat View 4.02 for Macintosh was used to analyze the data. Nonparametric tests were 
used. Wilcoxon’s signed rank test was used for the calculation of paired differences 
and the Mann-Whitney U-test was used for the calculation of unpaired differences. 
Spearman’s rank correlation was used for the calculation of correlation coefficients 
between isometric muscle strength and motor function/hand function, ROM and 
motor function/hand function and between isometric muscle strength and ROM. 
The correlation values were interpreted according to guidelines adapted from Alt-
man 103, where r<0.20 poor, 0.21–0.40 fair, 0.41–0.60 moderate, 0.61–0.80 good, 
and 0.81–1.00 very good. The level of significance was determined to be 0.05.
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Results
Survey results
In a nationwide study of arthrogryposis in children and adolescents in Sweden, 131 
individuals were investigated. Ages ranged from newborn to 28 years of age, with a 
mean age of 8.25 years; 59 females and 72 males. The majority of included individu-
als were under 20 years of age at the time of investigation. Diagnostic groups are 
presented in table 2. 
Amyoplasia was diagnosed in 48 (37%) patients; 35 (27%) of these were regarded 
as definite and 13 (10%) as probable amyoplasia. Five had only upper limb involve-
ment, eight only lower limb involvement, four lower limb plus discrete additional 
contractures (jaw/ thumbs/unilateral hand/bilateral hands). Of the remaining 31 
patients with involvement of all four limbs, one had dysmelia of the feet and one had 
Blackfan Diamond anemia in addition to amyoplasia.
DA was found in 27 (21%) index patients. Sixteen were autosomal dominant and 11 
were sporadic cases. Among the sporadic cases, five had DA1, one DA2B, Sheldon 
Hall syndrome, and there was one boy with DA3, Gordon syndrome, one boy with 
DA2A, Freeman Sheldon syndrome, and one girl and one boy each with DA8, mul-
tiple pterygeum syndrome. One young man was classified as having DA7, trismus-
pseudocamptodactyly syndrome. Among familial cases 10 had DA2B, four DA1, 
and one DA9, Beal syndrome, with autosomal dominant inheritance.
Six children had clinical signs of myopathy, none of these with specific myopathic 
diagnosis. Four children had Larsen syndrome, one further child had suspected Lar-
sen syndrome, one girl had Turner syndrome and one boy facio-audio-symphalang-
ism syndrome. Three children had suspected syndrome without MR: one boy with 
suspected Sprenger syndrome, one girl with severe hearing impairment and arthro-
gryposis and one boy in whom signs of a not defined syndrome were present.
Twenty-two (17%) children were found to have arthrogryposis with CNS-involve-
ment. Of these, one had a perisylvian syndrome, one agenesia of the corpus cal-
losum, one Marden Walker syndrome, and one Schwartz-Jampel syndrome. There 
was one case each of triploidy mosaicism, trisomy 6q and trisomy 18q. One boy had 
clinical signs of Kabuki make-up syndrome. Fourteen children had non-defined 
syndromes with mental retardation and arthrogryposis. Four children also had in-
creased muscle tone/spasticity. 
Preliminary results from arrayCGH investigation in 11 patients with arthrogrypo-
sis, CNS-involvement and dysmorphic features indicate that microaberrations likely 
to be pathogenic are found in the same frequency (10-20%) as in patients with MR 
and dysmorphic signs without the additional finding of arthrogryposis 58, 104.
Six children had arthrogryposis in the lower extremities only, two of these with 
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vertebral anomalies and caudal regression syndrome. A further 12 children had ar-
throgryposis that we could not specify further at present.
Table 2.  Survey results.The 131 investigated individuals with arthrogryposis according 
to identified diagnostic groups. 
AMYOPLASIA N=48
Upper and lower extremities 31
Lower extremities 12
Upper extremities 5
DISTAL ARTHROGRYPOSIS N=27
DA1 9
DA2A, Freeman Sheldon syndrome 1
DA2B, Sheldon Hall syndrome 12
DA3, Gordon syndrome 1
DA7, trismus-pseudocamptodactyly 1
DA8, multiple pterygium syndrome 2
DA9, Beal syndrome 1
CNS/MENTAL RETARDATION N=22
Spasticity 4
Perisylvian syndrome 1
Marden Walker syndrome 1
Schwartz-Jampel syndrome 1
Kabuki syndrome 1
Mosaic triploidy 1
Trisomy 6q 1
Trisomy 18q 1
OTHER SYNDROMATIC N=10
Larsen syndrome 5
Facio-audio-symphalangism syndrome 1
Turner syndrome 1
Not defined syndrome 3
MYOPATHIC SIGNS N=6
LOWER LIMB ARTHROGRYPOSIS N=6
Vertebral anomalies 2
Other 4
OTHER ARTHROGRYPOSIS N=12
TOTAL NUMBER N=131
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Paper 1
Muscle involvement and motor function in amyoplasia
Patients
Thirty-five individuals (28%) were diagnosed with definite amyoplasia. The diag-
nostic inclusion criteria were typical contractures at birth, muscle involvement, and 
associated findings such as dimpling and facial hemangiomas 3. There were 23 males 
and 12 females. The age at investigation ranged between 0.2 and 22.8 years, with a 
median age of 7.0 years. Involvement of only the upper limbs was seen in four, only 
the lower limbs in six and both the upper and lower limbs in 25 patients.
Eleven cases were categorized as community ambulators, 11 cases as household am-
bulators and seven as non-ambulartors.
Gestational and perinatal information 
There were three cases of twin pregnancies. Early spontaneous abortion of one fe-
tus was seen in two of these, leading to birth of affected singletons. The third twin 
pregnancy resulted in the birth of one affected girl and one healthy boy. There were 
two documented cases of maternal bicornate uterus, one of oligohydramnios and 
one of fetal ascites. Twenty mothers described decreased or other abnormal fetal 
movements. Three cases of pre-eclampsia and one of placental insufficiency were 
described. Ten children were delivered by Caesarian section and two by vacuum 
extraction. Eight children were born in breech presentation, one in foot presentation 
and 12 in normal presentation. Information about presentation is missing in two 
cases. Twenty-seven children were born at term and 7 were premature (gestational 
age ranging from 33 weeks to 36 weeks and 5 days). In one case information about 
gestational age is missing. Birth weight was within normal range in 27 children, 
there were six children with low birth weight (<2,500 g) and one with very low birth 
weight (<1,500 g). One child was born with gastroschisis and one with an inguinal 
hernia. In one child fractures occurred during delivery.
Joint Position at Birth
Twenty-three children were born with internal rotation of the shoulders. The elbows 
were extended in 22 children and flexed in seven. Flexion deformities at the wrist 
were noted in 24 children. Seven children were born with flexion, external rotation 
and abduction of the hips with flexed knees. Eleven children were born with extend-
ed or hyperextended knees. The most common foot deformity was pes equinovarus 
adductus seen in 24 children. There were four children with isolated short Achilles 
tendon and one child with pes calcaneovalgus.
Orthopedic operations
Nine hip dislocations were found in seven patients. Open reduction was performed 
in three patients/four hips. Extending osteotomies had been performed in two pa-
tients/four knees. The original deformity recurred after two to three years in these 
patients. Posterior soft tissue release had been performed in seven patients/14 knees, 
and quadriceps lengthening was performed in six patients/9 knees.
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Lengthening of the Achilles tendon was performed in nine patients. Six of these pa-
tients were subject to repeated surgery. Eleven patients underwent surgery with pos-
terior release as the primary operation and in six of these patients repeated surgery 
was performed. Talectomy as the primary orthopaedic operation was performed in 
three children under the age of two years. The median age of two months at the 
first operation was lower in 13 patients requiring repeated surgery, compared to the 
median age of two years in 11 patients who were operated on only once. 
In the upper limbs 28 operations were performed in 12 patients. Transfer of muscles 
(m. latissimus dorsi, m. deltoideus, m. pectoralis major) to restore active elbow flex-
ion was performed in six patients. One or several lengthening procedures or releases 
of the triceps tendon to increase ROM were performed in four patients. Six patients 
underwent surgery of the hand. Operations included transfers, lengthening, or re-
lease of tendons, capsulotomies and, in one case, an extending osteotomy with the 
main purpose of treating wrist flexion and thumb-in-hand deformities.
Stretching
All children except one had received regular stretching during their first years of 
life. The frequency varied from three to four times per week up to three to five times 
daily. After the first year the frequency gradually decreased, but in most patients 
stretching was continued two to three times per week. Splints were frequently used 
to increase or maintain joint motion during the first year of life, and later to main-
tain range of motion after orthopaedic surgery.
Isometric muscle strength
All investigated muscle groups, except elbow extensors in the household ambula-
tors, were significantly weakened compared with reference values 100. The most se-
verely reduced isometric muscle strength was found in non-ambulators. They were 
significantly weaker than household ambulators in elbow extensors (P=0.013), hip 
flexors (P=0.037), hip abductors (P=0.004), and knee extensors (P=0.001). Non-am-
bulators were significantly weaker than community ambulators in shoulder abduc-
tors (P=0.001), elbow extensors (P=0.006), wrist dorsiflexors (P= 0.002), hip flexors 
(P<0.001), hip extensors (P<0.001), hip abductors (P<0.001), knee flexors (P=0.043), 
knee extensors (P=0.001), and ankle dorsiflexors (P=0.012). Household ambulators 
were significantly weaker than community ambulators in hip flexors (P<0.001), hip 
extensors (P<0.001), hip abductors (P=0.001), knee flexors (P=0.004), and knee ex-
tensors (P<0.001). There was no significant difference in the muscle groups of the 
upper extremities between household ambulators and community ambulators.
Range of motion at time of investigation
The most severe contractures were found in non-ambulators. Non-ambulators had 
significantly more severe contractures than household ambulators in shoulder ab-
duction (P=0.019), elbow flexion (P=0.002), hip extension (P=0.019), knee exten-
sion (P=0.001), and knee flexion (P=0.038). Non-ambulators had significantly more 
severe contractures than community ambulators in shoulder elevation (P=0.048), 
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elbow flexion (P=0.001), hip extension (P=0.001), hip abduction (P=0.023), hip ad-
duction (P=0.037), hip inward rotation (P=0.003), knee extension (P<0.001), ankle 
dorsiflexion (P=0.002), and plantar flexion (P=0.001). Household ambulators had 
significantly more severe contractures than community ambulators in hip extension 
(P=0.034), hip internal rotation (P=0.006), knee flexion (P=0.008), knee extension 
(P=0.001), ankle dorsiflexion (P=0.010), and plantar flexion (P=0.001).
Motor Function
Motor function scores were related to age in all the assessed individuals. The young-
est children had poor motor function scores partly due to their age. Community 
ambulators had the highest scores and none-ambulators the lowest. Community 
ambulators achieved independent walking at an earlier median age compared to 
household ambulators.
Hand Function
Nine patients had normal hand function, 13 were able to perform tasks completely 
but with compensatory strategies, four were able to perform tasks incompletely and 
with compensatory strategies, and nine patients were able to perform tasks incom-
pletely with very limited hand function. 
Main correlations
There were strong correlations between muscle strength and motor function. There 
were only moderate correlations between range of motion and motor function. Com-
munity ambulators had the best muscle strength, and none had knee flexion con-
tractures of more than 20 degrees. Household ambulators had severe contractures in 
the legs, but good muscle strength in the arms. Non-ambulators had the most severe 
joint contractures and the most pronounced muscle weakness. The majority were 
born with hips in pronounced abduction, flexion and external rotation.
Paper 2
A mutation in the fast skeletal muscle troponin I gene causes myopathy and distal 
arthrogryposis
Patients
This family included five affected individuals in three generations at the time of 
investigation: the index patient who was a young girl, her father, paternal aunt and 
paternal uncle as well as her paternal grandfather. The clinical findings were, in 
summary, mainly distal joint involvement and mild facial involvement (mild mi-
crognathia, narrow palpebral fissures). There was no evident muscle weakness. 
Blood chemistry and neurophysiology
In all four affected adults, S-CK levels were mildly elevated at the time of investiga-
tion, ranging between 5.7 and 7.9 μkat/L (reference interval <3 μkat/L). In one case 
urine myoglobin concentration before and after exercise was measured and found to 
be normal. EMG was performed in one case. A small amount of denervation activity 
was found, but there were no convincing myopathic findings.
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Muscle morphology
Similar myopathic changes were found in all four adult cases. There was an in-
creased variability of fiber size and frequent muscle fibers with internalized nuclei. 
Fiber size variability was present among type 1 as well as type 2 fibers but was more 
pronounced among type 2 fibers, which were generally much larger than the type 
1 fibers. Occasional signs of fiber splitting in type 2 fibers were present. The fibers 
with internalized nuclei were type 2. There was type 1 fiber predominance (which is 
normal for the tibialis anterior muscle) except in one case where the area occupied 
by type 2 fibers was equal to or larger than that of type 1 fibers. Regenerating fibers 
and increased interstitial connective tissue was also found.
Genetic findings
We performed mutation analysis of TNNI2 in 16 members of the family. The entire 
coding sequence of TNNI2 was investigated in the index patient. We identified 
a heterozygous three-base in-frame deletion, 2,918–2,920del, skipping the highly 
conserved lysine (K) at position 176. The K176del is located in the distal end of the 
TNNI2 filament, seven residues from the stop codon. The deletion was identified in 
all five affected family members and not in any of the 11 investigated relatives with-
out DA. The mutated residue is highly conserved among species and corresponds to 
residue K206 in cardiac TnI (cTnI; TNNI3). A mutation of this residue, K206Q in 
cTnI, has been associated with hypertrophic cardiomyopathy 105.
Paper 3
Distal arthrogryposis and muscle weakness associated with a ß-tropomyosin 
mutation
Patients
We investigated a mother and daughter (index patient), age 65 and 28 years respec-
tively at time of investigation. Both had predominantly distal joint contractures 
at birth. At the time of investigation, the mother had contractures in jaws, hands, 
feet, elbows and shoulders and scoliosis. The daughter had contractures in all joints, 
proximal and distal, proximal syndactyly in the hands, and kyphosis. Both patients 
had short stature, and both had muscle weakness in proximal and distal muscles, 
most prominent in the hands and feet. The mother described progressive muscle 
weakness. Results of cardiac investigations were normal. The clinical findings were 
consistent with DA2B. No other family members were affected.
Genetic findings
We performed mutation analysis of the the entire coding sequence of TPM2 in the 
index patient. A heterozygous missense mutation in exon 4, C5396T, was identified.
The mutation was also present in the mother, but it was not identified in any of the 
three investigated relatives without DA (father and maternal grandparents), or in 
200 control chromosomes. 
Muscle morphology
Muscle biopsies were obtained from the tibialis anterior muscle in both patients. 
Histochemical and ultrastructural investigation revealed type 1 fiber predominance 
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but no other major morphologic abnormalities. Immunohistochemistry of myosin 
isoforms also demonstrated a marked predominance of muscle fibers expressing slow 
myosin.
Paper 4
Embryonic myosin heavy chain mutations cause distal arthrogryposis and deve-
lopmental myosin myopathy that persists postnatally
Patients
Patients 1 and 2 were a mother and daughter with DA2B, with clinical features in-
cluding short stature, scoliosis, mild facial dysmorphism, joint contractures in proxi-
mal and distal joints, and muscle weakness.
Patient 3 was  a man with a milder form of DA2B, father of three children who all 
had DA.  Clinical features included contractures in the hands and mild involvement 
of jaws, feet, and elbows, and normal muscle strength. 
Patient 4 was a boy with sporadic DA2A, Freeman Sheldon syndrome with facial 
contractures, small mouth, ptosis, short stature, and joint contractures in the proxi-
mal and distal joints. Muscle strength was difficult to evaluate owing to his young 
age, which was four years at the last assessment.
Genetic findings
The entire coding sequence of MYH3 was investigated in the index subjects of the 
respective families. Three different missense mutations were identified:
In patients 1 and 2 with DA2B, a heterozygous missense mutation in exon 13, 
A1454G, was identified. The mutation was de novo, and not present in the mater-
nal grandparents. In patient 3 with DA2B, a heterozygous missense mutation in 
exon 7, C769T, was identified. The mutation was also identified in all three affected 
children of patient 3 and also in the asymptomatic paternal grandfather. In patient 
4 with sporadic DA2A, a heterozygous missense mutation in exon 5, C602T, was 
identified. This was also an apparent de novo mutation, as neither of the parents car-
ried the mutation.
Expression of MYHC isoforms 
The relative expression of the 3 major MyHC isoforms in skeletal muscle and the 
presence of embryonic MyHC were determined at the messenger RNA level using 
reverse transcription-polymerase chain reaction analysis. None of the muscle biopsy 
specimens from the patients demonstrated expression of embryonic MyHC.
Muscle morphology 
Muscle biopsy specimens from the deltoid muscle in patients 1 and 2 exhibited slight 
pathological changes. There was increased variability of fiber size owing to the pres-
ence of frequent small type-1 fibers, and also a slightly abnormal type-1 fiber pre-
dominance. A muscle biopsy specimen from the deltoid muscle of patient 3 showed 
scattered, small type-1 fibers but no obvious pathological changes. Muscle biopsy 
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specimens from the tibialis anterior muscle of patient 4 at ages 15 months and five 
years showed slight pathological changes. The major abnormality at age 15 months 
was numerous fibers expressing the fetal (perinatal) isoform of MyHC (MYH8), and 
the biopsy specimen obtained at age five years showed marked type-1 fiber predomi-
nance and scattered, small type-1 fibers. No fibers expressed fetal MyHC at age five 
years in patient 4. Expression of embryonic MyHC (MYH3) was not identified in 
any patients.
Paper 5
Distal arthrogryposis: clinical and genetic findings
Patients
In the original study of 131 patients with arthrogryposis, 27 cases with DA from 
21 families were identified. Of the 27 index cases, 11 were sporadic and 16 familial. 
A further 13 affected relatives were identified and investigated. Including affected 
parents and extended family members, 40 individuals with familial or sporadic DA 
were interviewed and examined.
DA classification
Fourteen patients, seven familial and seven sporadic cases, were classified as having 
DA1 and 17 patients, 15 familial and two sporadic cases, were classified as having 
DA2B. In two familial patients clinical findings were intermediate between DA1 
and DA2B. Clinically, dividing lines between these two syndromes where not clear 
cut. 
One child was classified as having DA2A, Freeman Sheldon syndrome, one child as 
DA3, Gordon syndrome, and one young man as DA7, Trismus-pseudocamptodac-
tyly syndrome. These three were all sporadic cases. Multiple pterygium syndrome, 
DA8, was found in two sporadic cases, and Beal syndrome, DA9, in one family with 
affected mother and son. We did not identify any patients with DA4 (DA with sco-
liosis as the predominant feature), DA5 (DA with limited ocular motility), DA6 (DA 
with sensorineural hearing loss) or 10 (DA with plantar flexion contractures).
Perinatal data
Fourteen of 27 (52%) of the children were born by Caesarean section. Eight of these 
children were in breech position. Feeding problems in the neonatal period were common 
(60%).
At birth, hand involvement included ulnar deviation, thumbs in hand, clenched 
fists, contractures in fingers, contractures in wrists, and overlapping fingers. Foot 
involvement included pes equinovarus, pes calcaneovalgus, and other foot malposi-
tions. Asymmetric foot involvement was found in nine familial cases. Involvement 
of proximal joints included contractures in hips, knees, shoulders and elbows, dislo-
cation of hips, scoliosis/kyphosis, and torticollis. 
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Facial involvement
Facial involvement was found more frequently in familial than in sporadic cases. The 
most frequent findings, in decreasing order, were impaired mouth opening (mild 
contractures in jaw joints), low set ears, high arched palate, micrognathia, high nose 
bridge, down-slanting and/or narrow palpebral fissures, facial asymmetry, small 
mouth, and epicanthal folds. Prominent chin was not a frequent finding 
Hand involvement
Flexion or, more seldom, extension contractures in the wrist were the most frequently 
found involvement of hands, followed by ulnar deviation in wrists/fingers. Smooth 
palms with absent flexion creases and contractures in MCP and finger joints result-
ing in camptodactyly were also seen frequently. Thumbs in hands and other thumb 
malpositioning were also found. 
Foot involvement
Where foot malpositioning was present at birth, orthopaedic treatment had most-
ly taken place when patients were examined after the first year of life. The most 
common present types of foot involvement, in order of frequency, were ankle con-
tractures, adduction/metatarsus varus, prominent heel pads (also a common find-
ing in other types of arthrogryposis), overlapping toes, short Achilles tendons, pes 
planovalgus and equinus feet. Asymmetric involvement of the feet was a common 
finding, while asymmetric size of the feet was found in a few cases.
Involvement of proximal joints
Proximal joints were more often engaged in the upper limbs than in the lower limbs, 
with elbow contractures the most common finding. Impaired shoulder mobility was 
also relatively frequent. Contractures in the hips and knees were found in decreasing 
frequency. Asymmetric legs (length and/or muscle bulk, especially in calves) were 
also seen. 
Spinal involvement
Scoliosis was found in nine cases, kyphosis in two. Stiff spine, lumbar or thora-
columbar, was found in three cases. Short neck and/or contracted neck muscles were 
found in 15 cases. 
Short stature
Five individuals had a short stature, four familial and one sporadic case.
Gross motor function and hand function
Ambulation was affected in 4/38 patients: a mother and daughter with DA2B and 
MYH3 mutation, one sporadic case with DA2B and no identified mutation, and one 
sporadic case of DA8. 
Hand function was mildly affected in 28/40 patients (able to perform all tasks but 
with compensatory strategies or aberrant function), and impaired in 5/40 patients.
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Muscle involvement
Muscle weakness, generalised or in hands/feet, was found in 15/36 individuals: 8/29 
familial cases, five of these with an identified mutation (two MYH3, two TPM2 and 
one TNNI2), and 9/11 sporadic cases, one with an identified mutation (MYH3). 
Calves were thin in 11 familial and five sporadic cases. Muscle pathology had been 
demonstrated in 10/16 biopsied cases.
Orthopedic surgery 
The number of performed orthopedic operations varied between none and 22 in 
different individuals. The majority of operations were in the feet, with only a few in 
hands, proximal joints or spine.
Pain 
Pain, either generalised muscle pain or localised pain, was present in 16/39 patients. 
Pain was a more frequently occurring problem in patients with more severe joint 
contractures, and in patients who had undergone multiple surgeries. In several of the 
adult patients, muscle fatigue and pain on exertion was described.
Molecular genetics
Genetic investigation for mutations in genes encoding for sarcomeric proteins iden-
tified pathogenic mutations in 21/37 affected cases, 20/29 familial and 1/8 sporadi-
cally occurring. In three families, one with mutation in MYH3, one TPM2, and 
one TNNI2, the mutation was found to be de novo. Four asymptomatic carriers 
were found. In seven patients with DA2B, five familial cases from two families and 
two sporadic cases, and six patients with DA1, two familial and four sporadic, no 
mutation was identified. Clinical findings in these cases did not differ from cases 
were pathogenic mutations were identified. In one patient with DA8, no pathogenic 
mutation was identified on investigation.
Clinical vs genetic findings
In DA1 and DA2B families, symptoms did not comply with the different mutations, 
or even with whether a pathogenic mutation was found or not. This would indicate 
firstly that dysfunction of several different sarcomeric proteins during fetal life result 
in similar clinical symptoms, and secondly that the presence of so far non-identified 
gene mutations can cause the same clinical symptoms as the identified mutations in 
MYH3, TPM2 and TNNI2. 
The likelihood of identifying a genetic cause of DA was found to be far greater in fa-
milial than in sporadic cases. The only sporadic case of DA with an identified patho-
genic mutation in our study was a child with DA2A, Freeman Sheldon syndrome. 
However, in three families with familial DA a de novo mutation could be demon-
strated in the oldest affected individual, which demonstrates that pathogenic sarco-
meric gene mutations may also be present in other sporadic cases. In two extended 
families asymptomatic carriers were found, demonstrating varying penetrance.
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discussion
Amyoplasia (Paper I)
Patients
There were twice as many boys as girls in our study of muscle involvement and motor 
function in 35 children with amyoplasia, and boys were also more severely affected 
than girls. The reason for this is unclear. In a review of AMC by Hageman et al 106 a 
sexratio of two boys to one girl is described, referring to a publication by Kite from 
1955. As far as we know this relationship has not been found in other studies. How-
ever, in our background survey of arthrogryposis in 131 cases in Sweden with a total 
of 48 patients with definite or possible amyoplasia, the male preponderance was not 
as high: 28 boys/20 girls. 
Joint contractures
The extent and severity of joint contractures are important predictors of ambula-
tory level and motor function outcome in amyoplasia. Patients who turned out to 
be non-ambulators or household ambulators had a larger number of joints involved 
at birth compared to community ambulators. The combination of lower limb joint 
contractures and severe muscle weakness is negative for ambulation development. 
In non-ambulators, the typical joint positions at birth in lower extremities were 
flexion, abduction, and external rotation in the hips with knee flexion contractures. 
However, with good muscle strength in the upper extremities some of the patients 
with this combination of congenital contractures became household ambulators and 
used walking aids for support. The importance of good hand function for the ability 
to use walking aids has been described previously 102, as has the importance of con-
tractures in level of ambulatory function 65, 107. Non-ambulators all had severe flexion 
contractures in the hips and knees. The negative impact on flexion contractures in 
the lower extremities on the ability to walk has also been demonstrated in previ-
ous studies. More than 20 degrees of flexion contractures in the knees make use of 
orthoses for ambulation impossible108. Flexion contractures in the lower extremities 
also seem to be more difficult to treat successfully 50.
Orthopedic treatment
The majority of performed orthopedic operations were in the feet. Achilles tendon 
lengthening and posterior release often had to be repeated, especially if performed 
at an early age (during the first four months). No community ambulators had been 
subject to hip surgery, and only one had knee surgery, while surgery in hips and 
knees was more often performed in household ambulators and non-ambulators, 
a consequence of their more severe contractures in the lower extremities. Surgery 
in the upper limbs mainly included tendon transfers and lengthenings to increase 
range of motion. Although increased range of motion was often achieved, functional 
improvement was rare. 
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Muscle strength 
The most important finding in our study was that muscle strength is more impor-
tant than joint contractures in the development of motor function. This implies that 
muscle mass in the infant with amyoplasia is more important than severity of joint 
contractures in predicting future motor abilities. Muscle mass can be difficult to 
evaluate on inspection, as the small infant has a relatively large amount of adipose 
tissue that may disguise lack of muscle bulk. Functional assessment (observation of 
the baby s´ spontaneous motor function) and ultrasound/CT scan/MRI to evaluate 
muscle bulk are ways to get a better evaluation. The importance of muscle strength 
in development of motor function/level of ambulation in children also has implica-
tions in the planning of treatment.
Distal artrogryposis (Papers II-V)
Clinical and genetic findings
Clinical findings were found to be highly variable in individuals with DA. This was 
true also between families, and within families with DA. Familial cases were often 
found to have more severe symptoms than sporadic cases, but this was not true of 
all patients.
In DA1 predominantly distal joint contractures with no associated anomalies are 
described, whereas in DA2B, Sheldon Hall syndrome, mild facial involvement (tri-
angular face, down-slanting palpebral fissures, prominent nasolabial folds, small 
mouth), sometimes asymmetric foot involvement and short stature are typical find-
ings 76. In DA2A, Freeman Sheldon syndrome, severe facial involvement with small 
and pursed mouth, joint contractures, and short stature are common findings. The 
majority of cases in our study were diagnosed with DA1 or DA2B. We found that 
the clinical division between the two syndromes was unclear, especially in patients 
where facial involvement was very mild. Both syndromes were found in sporadic 
and familial patients, although familial involvement was more common in DA2B. 
The only other familiar patients found were a mother and son with DA9. Other DA 
forms found were all sporadic cases of DA2A, DA3, DA7 and DA8. We found no 
cases of DA4, DA5, or DA6. DA1 and DA2B are the most commonly occurring 
forms of DA 6, 21, while other forms are more rare. 
Mutations in genes encoding sarcomeric (contractile) muscle proteins are involved in 
DA syndromes. Genes initially found to be involved in DA are troponin I (TNNI2), 
troponin T (TNNT3), and β-tropomyosin (TPM2). Mutations in TPM2 can also be 
found in nemaline myopathy 109 and cap disease 110. Recently, mutations in MYH3 
have also been found in DA syndromes 21. There are several known myosin myopa-
thies: familial cardiomyopathy, myosin storage myopathy, Laing early onset myopa-
thy and autosomal dominant myopathy with rimmed vacuoles, ophtalmoplegia and 
congenital joint contractures 111. The pathogenic mechanisms in sarcomeric protein 
dysfunction leading to myopathy and DA have been unclear. Increased contractility 
of developing fast-twitch skeletal muscles, causing muscle contraction and secondary 
joint contractures has been a proposed pathogenic mechanism 112.
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Earlier studies have shown that fetal immobility is the common background for all 
arthrogryposis syndromes. Defective muscle relaxation may lead to fetal immobility 
and arthrogryposis. Troponin and tropomyosin are both involved in the regulation 
of muscle contraction. In a study of R133W β-tropomyosin mutation on regulation 
of muscle contraction in single human muscle fibers, results indicate that the muta-
tion induces alterations in myosin-actin kinetics causing a reduced number of myo-
sin molecules in the strong actin-binding state, resulting in overall muscle weakness 
without simultaneous muscle wasting 99.
Myosin is an essential part of the thick filament in striated muscle (paper IV). The 
expression of myosin heavy-chain (MyHC) is developmentally regulated. The em-
bryonic isoform encoded from MYH3 is expressed during fetal life. In muscle biopsy 
specimens from patients with DA and MYH3 mutations, the embryonic isoform 
of MyHC (MYH3) was not detected. This indicates a normal down regulation of 
MYH3. On morphologic analysis, mild and variable pathologic changes were found, 
and in one patient also pathologic upgrading of the fetal MyHC isoform (MYH8). 
These findings indicate that DA syndromes are caused by myopathies with onset 
during fetal life, and that postnatal muscle manifestations are variable.
 
TNNI2
Two families with a pathogenic TNNI2 mutation were identified. In the first fam-
ily a novel K176del mutation was found in all affected individuals (paper II). The 
clinical findings in six affected individuals (five at the time of primary investiga-
tion; one more child born during the study) included distal joint contractures but 
also involvement of proximal joints, short neck muscles, and mild facial involve-
ment including mildly narrowed palpebral fissures and a high arched palate. The feet 
were asymmetrically involved in one individual. Clinical findings were intermediate 
between DA1 and DA2B. One further family with a different TNNI2 mutation, 
R174Q, in three affected individuals (mother and two children) was identified in 
our study. This mutation has previously been reported in DA2B 4. In this family, 
clinical findings were more consistent with DA2B. Muscle weakness was not appar-
ent in the first described family, while muscle weakness was present in one investi-
gated individual in the second family. In the first of these two families, the mutation 
was most likely de novo.
TPM2
One family with a novel TPM2 mutation, R133W, was found (paper III). The two 
patients, mother and daughter, had contractures predominantly in distal joints but 
also proximal joint involvement, smooth palms, short stature, and spinal involve-
ment. Both had muscle weakness in proximal and distal muscles, most prominent in 
the hands and feet. The mother described progressive muscle weakness. The clinical 
history and findings were consistent with DA2B. The mutation was found to be de 
novo.
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MYH3 
Three families and one sporadic case with MYH3 mutations were identified. In the 
first family (patients 1 and 2 in paper IV) with a D462G mutation, the affected 
mother and daughter both had severe joint involvement in both distal and proximal 
joints, relatively mild facial involvement, spinal involvement, short stature, asym-
metric foot involvement, all consistent with DA2B. Both had weak muscles. The 
mutation found was de novo.
In the second family, a A234T mutation in MYH3 was found in the affected father 
(patient 3 in paper IV), in his three affected children, but also in the unaffected 
paternal grandfather. Clinical signs were consistent with DA2B in the father and in 
one child, whereas in the other two affected children there was no facial involvement 
and clinical findings were more like DA1. Clinical features in affected family mem-
bers included contractures primarily in the hands and/or feet, mild involvement of 
the jaws and elbows, and normal muscle strength. In one child with predominantly 
hand involvement the contractures seemed to be progressive, which is an unusual 
finding. Incidentally, in the extended family the maternal grandfather was found 
to have DA1 and a different mutation in MYH3, A1198T. This mutation was also 
found in his two unaffected sons but not in his also unaffected daughter (mother of 
the three affected children).
In a third family, an A1752T MYH3-mutation was found in two brothers, father 
and an unaffected paternal grandmother. The older brother also had a mild mental 
retardation and the younger additional malformations (cleft palate, bowel atresia 
and VOC). Both had attention deficit hyperactivity disorder, ADHD. The father in 
this family had a history of contractures in his feet as a child, but was asymptomatic 
at the time of investigation. The mutation found in this family was considered to be 
a possible polymorphism.
Finally, a T178I MYH3-mutation was identified in a boy with DA2A, Freeman-
Sheldon syndrome (patient 4 in paper IV). Symptoms included ptosis, blepharophi-
mosis, short stature, small and contract mouth, and joint contractures in proximal 
and distal joints.
DA with no identified mutation
We found two families with DA2B, one with an affected mother and son, and the 
second family with an affected father and two sons, with typical symptoms in both 
families including mild facial involvement, predominantly distal joint contractures 
and asymmetric foot involvement in several patients, and no identified mutation in 
investigated genes. Symptoms in these two families with DA2B were no less severe 
compared to those where a pathogenic mutation in genes encoding for sarcomeric 
proteins were identified. No pathogenic mutation was identified in sporadic cases 
except the one child with DA2A.
Phenotypic variability in DA is well described previously 78, 113. Clinical features of-
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ten overlap, especially between DA1 and DA2B and between DA2B and DA2A 114. 
Mutations in MYH3, TNNI2, and TNNT3 have been described in approximately 
50% of cases with DA2B, Sheldon-Hall syndrome, in previous studies 4 TPM2 mu-
tations in DA2B have also been found recently 114.
In a study of MYH3-mutations in patients with DA2A and DA2B by Toydemir 
21, a mutation was found in 58% of investigated cases. According to Bamshad 114, 
mutations in MYH3 have been found in approximately 90% of DA2A, and 40% 
of DA2B cases, and mutations in TNNI2, TNNT3, and TPM2 have been found 
in DA1 and DA2B, suggesting variable expressivity of the same syndrome. Other 
sarcomeric protein genes involved in DA are MYH8 in DA7, where a single missense 
mutation has been found in studied families 22, and MYH2 and MYH13 found 
in two families with DA5 (DA with ophtalmoplegia and ptosis). Both MYH2 and 
MYH13 are expressed in skeletal and extraocular muscles 114.
We identified mutations in TNNI2 in nine cases with DA1 and DA2B, a TPM2 
mutation in two cases with DA2B, and MYH3 mutations in nine DA1, one DA2A 
and three  DA2B cases.
Muscle morphologic findings and muscle weakness
Muscle biopsy performed in four affected adults with a TNNI2-mutation revealed 
mild myopathic changes. There was an increased variability of fiber size, frequent 
internalized nuclei, and signs of muscle fiber regeneration and increased interstitial 
connective tissue in some cases. The structural changes and internalized nuclei were 
mainly confined to type 2 muscle fibers, which express the mutant TnI isoform. 
Muscle weakness was not found in these four patients, but in the oldest patient, 
who also had the most prominent muscle morphologic findings, muscle fatigue was 
described.
Histochemical and ultrastructural investigation of muscle biopsies in the two af-
fected individuals with TPM2-mutation revealed type 1 fiber predominance but no 
other major morphologic abnormalities. Immunohistochemistry of myosin isoforms 
also demonstrated a marked predominance of muscle fibers expressing slow myosin. 
Muscle weakness was found in both patients.
Muscle biopsy specimens in affected patients with MYH3-mutations, patients 1 and 
2 (paper IV) exhibited increased variability of fiber size owing to the presence of fre-
quent small type-1 fibers, and slightly abnormal type-1 fiber predominance. These 
two patients both had muscle weakness. A muscle biopsy specimen from patient 3 
(paper IV) showed scattered, small, type-1 fibers but no obvious pathologic changes. 
This patient had no muscle weakness. Muscle biopsy specimens from patient 4 (pa-
per IV) showed slight pathological changes; at age 15 months there were numerous 
fibers (>20% of all fibers) expressing the fetal (perinatal) isoform of MyHC (MYH8), 
and at age five years there was type-1 fiber predominance and scattered small type-1 
fibers. In this patient, muscle weakness was also found.
50
Discussion
Clinical involvement in individuals with DA and MYH3-mutations is highly vari-
able, from very mild or no joint involvement to severe contractures. DA associated 
with MYH3 mutations is secondary to myosin myopathy, and postnatal muscle 
manifestations are variable.
Mutations in the same gene were found in different DA syndromes, suggesting vary-
ing clinical penetrance and expression rather than separate genetic syndromes and, 
vice versa, different gene mutations were found in the same clinical syndrome sug-
gesting multiple gene background.  
DA has previously been defined as an inherited primary limb malformation disorder 
characterized by congenital contractures of two or more different body areas and 
without primary neurologic and/or muscle disease that affects limb function 7. 
We suggest that the present classification of DA syndromes could be modified, and 
DA syndromes re-defined according to pathogenic findings, i. e. sarcomeric protein 
dysfunction, connective tissue dysfunction or other pathology. DA1, DA2B,Sheldon 
Hall syndrome, and DA2A, Freeman Sheldon syndrome, may then be regarded as 
related syndromes with fetal sarcomeric myopathy of increasing severity. At least 
DA5 and DA7 also belong to this group of DA syndromes caused by sarcomeric 
protein dysfunction. In DA8, mutations both in TPM2 and in acetylcholinreceptor 
genes have been described, and DA9 is known to be caused by a mutation in FBN2, 
and so should rather be regarded as a collagen dysfunction disorder.
Molecular genetic and muscle pathology investigations, in addition to careful clini-
cal evaluation including evaluation of muscle strength and joint involvement, are of 
importance in patients with DA syndromes in order to further define and under-
stand these disorders. 
General discussion
Epidemiology
The birth prevalence of multiple congenital contractures was found to be 1/5100 
live born children in an epidemiological study from western Sweden 49. Based on 
this study, there should be approximately 1800 individuals with arthrogryposis in 
Sweden, 400 of which should be individuals of 18 years and younger, with a present 
total population of 9.3 million and 2.05 million of 18 years and under. However, 
there is an increased mortality in many syndromes with arthrogryposis, especially 
those with CNS-involvement, so the actual number of present cases can be assumed 
to be lower. In our study of arthrogryposis primarily in children and adolescents, we 
investigated 131 index cases, with a further 13 affected relatives. It can be assumed 
that we saw a maximum of 1/3 of all present cases in children and adolescents in 
Sweden. The reasons for “missed” cases are several: first, not all cases are registered at 
the local rehabilitation center; second, not all cases are registered under the diagnosis 
of arthrogryposis; third, not all families who had children with arthrogryposis were 
considered suitable to partake in the study at the present time by the local reha-
bilitation professionals and therefore not asked; and fourth, some families declined 
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participation in the study. We also assume that some of the cases with mild joint 
involvement may not have any medical contacts at all, or sporadic contact with an 
orthopedic/hand surgeon. The children who were not identified as having the diag-
nosis of arthrogryposis in spite of the presence of multiple congenital contractures 
were mainly those who had a diagnosis of congenital myopathy/muscle dystrophy 
or diagnosed genetic syndromes/malformation syndromes. Children with myelom-
eningocele were not included in the study. These children often have arthrogryposis 
in the lower extremities, but as a group they are well defined and described in other 
studies, and the causes are well known. 
Classification
The majority of cases investigated did not have a specific diagnosis other than arthro-
gryposis at the time of investigation. In some cases, further medical investigations 
such as muscle biopsy or radiology investigations were needed to clarify the diagno-
sis, but in many cases careful clinical evaluation by professionals with experience in 
evaluation of children with arthrogryposis was sufficient. Both in amyoplasia and 
in DA syndromes, as in many types of arthrogryposis, diagnosis is based on clinical 
evaluation. An evaluation by a clinical geneticist was also invaluable in a number of 
cases, mainly those with specific malformation syndromes or dysmorphic features. 
Our conclusion is that a multidisciplinary evaluation by an experienced arthrogry-
posis team is needed for a correct diagnosis in the majority of cases.
The relatively high proportion of amyoplasia/probable amyoplasia (37%) and distal 
arthrogrypos (21%) patients in our study is probably due to the fact that these are 
the most typical arthrogryposis diagnoses, while other causes may not be as obvious. 
Intellectual abilities are generally not affected in these syndromes, but in the arthro-
gryposis group as a whole mental retardation is present in approximately 25% of all 
subjects 52. In our study mental retardation/CNS involvement was present in at least 
16% (at least two more patients had a suspected mental retardation, but were too 
young to be evaluated). This is a lower frequency than has previously been reported, 
probably due to the described bias in reported patients.
Assessment 
There is a need for expert teams with clinical experience of diagnostics and treat-
ment in arthrogryposis. There are many different syndromes, often rare disorders, 
the clinical picture can be complicated, and arthrogryposis often leads to severe 
disabilities. A correct diagnosis is important in order to give a relevant prognosis, 
inform about possible risk of recurrence, and to plan treatment. The first contact 
should be as early as possible, preferably already in the neonatal ward. Repeated 
functional assessments are often necessary. Early treatment should be initiated, 
avoiding immobilisation as far as possible. Treatment must always be planned in 
close collaboration with the family and the local rehabilitation team. A multidisci-
plinary approach is needed, with pediatric neurologist, clinical geneticist, orthope-
dic surgeon, hand/plastic surgeon, physical therapist, occupational therapist, and 
orthopedic technician. Other specialists that are often involved are neonatologist 
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for the newborn, dentist, nutritionist, and others. Regional referral teams may be 
a solution, even though the patient organisation advocates a national competence 
center for arthrogryposis. 
Aspects of treatment
Information about given treatment was difficult to evaluate and validate. For the 
majority of cases, a specific diagnosis was not available prior to our investigation, so 
in planning treatment the underlying cause of arthrogryposis in the individual child 
was not known. Since joint contractures in amyoplasia have been found to be more 
resistant to treatment than in DA 50, 65 this information is necessary to compare and 
evaluate treatment results. 
Given treatment was also difficult to recapitulate: The amount of actual stretching 
(how many times a day, which joints, for how long time, etc) was almost impossible 
to assess, as documentation and parents recollection could differ considerably. The 
same was true regarding splinting, were prescribed splints where not always used, at 
least not as assumed in the medical records. Records of casting and actual orthopae-
dic surgical interventions were easier to collect from medical charts, but even then 
it was sometimes difficult to find the duration of casting and also the exact surgical 
procedure performed. The results of treatment given was also difficult to evaluate 
in retrospect, as the opinion of the orthopaedic surgeon, the physiotherapist, the 
parents and, in cases where the child was old enough, the patient could differ con-
siderably. 
Functional outcome is the most important aspect of treatment. In our study of 
amyoplasia, we found that muscle strength is more important than severity of joint 
contractures for the ability to move/walk. In amyoplasia, muscles are absent or se-
verely dysplastic due to anterior cell dysplasia 15. Usually, not all muscle groups are 
involved, and commonly muscles in the trunk, neck and face are spared. It has been 
assumed that the underdeveloped muscles do not regenerate, but one recent study 
has shown increase of muscle mass as demonstrated with MRI studies of muscle in 
one child in infancy and again at five years of age 55. This finding has important im-
plications for treatment and underscores the importance of stimulating muscle use 
and activity even in very weak muscles in amyoplasia. Ultrasound or MRI investiga-
tion of muscle in the neonatal period should be useful to evaluate the possibilites for 
future muscle strength development and to predict results of treatment.
Early intensive treatment (stretching and splinting) has been found to be especially 
important in amyoplasia. Casting, especially during the first three or four months, 
should be minimized 5,50. In planning surgery, it is essential to carefully assess mus-
cle bulk and muscle function to make sure the planned intervention does not impair 
future motor abilities.
Problems with muscle pain and increasing muscle fatigue have been described by 
adults with amyoplasia and DA. The symptoms described are similar to those found 
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in post-polio syndrome, with increasing symptoms in older patients due to lack of 
reserve capacity in the muscles.
In DA, the pathogenic background is different. In the most commonly occurring 
DA syndromes, DA1 and DA2B with the present nomenclature, a “new” kind of 
myopathy with defects in sarcomeric proteins affecting the contractile function in 
striated skeletal muscles, expressed mainly during fetal life, has been demonstrat-
ed. The muscle weakness resulting in congenital, mainly distal joint contractures 
is presumably at maximum during fetal life. This fetal myopathy can result in mild 
myopathic findings in adult muscle, and also in muscle weakness in adult life. There 
are, however, no signs of progressive myopathic symptoms in our investigated pa-
tients, other than increasing muscle fatigueability with increasing age. Congenital 
contractures in DA have been reported to be easier to correct than in amyoplasia 5, 
even though, in our study, we found individuals with severe joint involvement who 
had been subject to multiple surgical corrections. The implications for treatment of 
muscle findings in DA may be that care should be taken not to “over-exercise”, in 
order to avoid pain and fatigue in muscles with increasing age, and in DA as well 
as in amyoplasia care should be taken not to cause additional muscle atrophy and 
weakness by immobilisation or muscle damage due to the surgical procedure when 
treating joint contractures.
Other aspects of treatment must also be taken into consideration. Jaw involvement 
is a frequent finding, both in amyoplasia and in DA. Feeding difficulties in infancy 
are common. Anesthesiological implications are difficulties with intubation. Ma-
lign hyperthermia is described in rare cases of arthrogryposis 70. As children with 
arthrogryposis are often subject to repeated surgical treatment, care must be taken 
with pain management and to avoid painful procedures as far as possible. Other 
than postoperative pain, pain found in children with arthrogryposis in our study 
was related to multiple surgeries, especially in the feet. The general development and 
wellbeing of the child must also be considered in planning treatment. The following 
parameters have been found to be important in preparing for an independent adult 
life in individuals with physical disabilities, in order of importance: 1: Communica-
tion skills. 2: Activities of daily living, 3:Mobility, and 4:Walking 50.  Consequently, 
time for play and interaction with peers are at least as important as treatment and 
training to achieve good motor function in the overall development of the child.
In summary
A correct specific diagnosis should be aimed for. Early physical therapy with stretch-
ing of joint and muscle contractures is important, and in the first 3-4 months of life 
especially rewarding. Active muscle use should be promoted, and immobilisation 
should be avoided as far as possible. Assessment of muscle strength and motor func-
tion should be done before surgery. It is important to care for pain management and 
avoid painful procedures, since these children are often subject to repeated surgical 
interventions.
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conclusions
A classification of the investigated patients with arthrogryposis into different specific 
diagnoses identified the three largest groups, in decreasing order, as amyoplasia, dis-
tal arthrogryposis syndromes and arthrogryposis with CNS-involvement.
In amyoplasia, muscle strength was reduced in the majority of patients. The extent 
of muscle involvement varied between individuals and also between muscle groups 
in the individual patient. Ultrasound or MRI of muscle tissue in the newborn period 
would be useful to evaluate prerequisites for future development of muscle strength 
and motor function, and thereby anticipate response to therapy. 
Muscle function in amyoplasia is more important than severity of joint contractures 
for the prediction of walking ability and functional level. Joint positions at birth are 
also of importance, especially for the prediction of ambulatory function. We con-
clude that more attention should be paid to development of muscle strength with 
early stimulation of active movements. Immobilisation should be minimized.
In distal arthrogryposis, pathogenic mutations in the same gene were found in dif-
ferent clinical syndromes, implying that these syndromes are expressions of vary-
ing clinical penetrance and expression of the found mutation rather than separate 
genetic syndromes. Different gene mutations were also found in the same clinical 
syndrome, suggesting multiple gene background. We conclude that DA syndromes 
are clinically and genetically heterogenous conditions.
A pathogenic mutation is more often found in familial than in sporadically occuring 
cases of DA, but de novo mutations are not uncommon.
In DA1, 2A and 2B pathogenic mutations were found in TNNI2, TPM2 and 
MYH3. Troponin, tropomyosin and myosin are sarcomeric proteins important 
for muscle contraction. We conclude that these DA syndromes are caused by fetal 
myopathy due to sarcomeric protein dysfunction causing muscle weakness and sec-
ondary joint contractures, and that DA syndromes may be re-defined according to 
pathogenic background.
In studying treatment of arthrogryposis, our main conclusion is that a careful clini-
cal evaluation by a team with experience in arthrogryposis as early as possible is 
important for correct diagnosis and planning of treatment, and that care should be 
taken to minimize immobilisation in order to avoid further muscle atrophy, espe-
cially during early life.
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